Person:
MAYADAĞLI, ALPASLAN

Profile Picture
Status
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
ALPASLAN
Last Name
MAYADAĞLI
Name
Email Address
Birth Date

Filters

Show more
Browse subject tree
2010 - 2019262020 - 20222
Reset filters

Settings

Author: Mayadagli, Alpaslan ×

Search Results

Now showing 1 - 10 of 28
  • No Thumbnail Available
    PublicationMetadata only
    Prognostic significance of protein kinase B/Akt pathway in patients with non-small cell lung cancer
    (2014-01-01T00:00:00Z) Mayadagli, Alpaslan; Gul, Sule Karabulut; Bilici, Ahmet; Oruc, Ahmet Fatih; Kocak, Mihriban; Ozkan, Alper; Aksu, Atinc; Barisik, Nagehan Ozdemir; Gumus, Mahmut; MAYADAĞLI, ALPASLAN
    Purpose: Akt, also known as protein kinase B (PKB), is an intracellular signal transduction protein activated by growth hormones. PKB/Akt is frequently activated in a variety of cancer types, but its role in the development and progression of lung cancer has not been completely elucidated yet. The aim of the present study was to determine the prognostic value of PKB/Akt in non-small cell lung cancer (NSCLC).
  • No Thumbnail Available
    PublicationMetadata only
    COULD PRETREATMENT PET-CT STANDART UPTAKE VALUES HAVE A ROLE IN THE RESPONSE TO TREATMENT AND THE SURVIVAL IN PATIENTS WITH SMALL CELL LUNG CANCER?
    (2013-11-01T00:00:00Z) Aydin, Kubra; Odabas, Hatice; Seker, Mesut; Korkmaz, Taner; Yasar, Nurgul; Sener, Nur; Aydin, Dincer; Ercelep, Ozlem; Yuksel, Sinemis; Mert, Aslihan G.; Aliustaoglu, Mehmet; Mayadagli, Alpaslan; Dane, Faysal; Gumus, Mahmut; MAYADAĞLI, ALPASLAN
  • No Thumbnail Available
    PublicationMetadata only
    Efficacy of stereotactic radiotherapy as salvage treatment for recurrent malignant gliomas
    (2014-10-01T00:00:00Z) Ekici, Kemal; Ozsekee, Naciye; Mayadagli, Alpaslan; Kocak, Mihriban Erdogan; Olmezoglu, Ali; MAYADAĞLI, ALPASLAN
    Purpose: To evaluate the efficacy and toxicity of CyberKnife stereotactic radiotherapy (SRT) for recurrent glial tumors previously treated with high-dose radiotherapy.
  • No Thumbnail Available
    PublicationMetadata only
    Salvage Chemoradiation therapy for Loco-regional Recurrence After Adjuvant Gemcitabine in Patients With Resected Pancreatic Adenocarcinoma
    (2012-11-01T00:00:00Z) Gemici, C.; Yaprak, G.; Tepetam, H.; Mayadagli, Alpaslan; MAYADAĞLI, ALPASLAN
  • No Thumbnail Available
    PublicationMetadata only
    The prognostic impact of survivin and REG1A in diffuse large B-cell lymphoma
    (2013-09-01T00:00:00Z) Seker, M.; Gumus, M.; Barisik, N. Ozdemir; Dane, F.; BOZKURT, SÜHEYLA; Bilici, A.; Seber, S.; Mayadagli, Alpaslan; Yumuk, P. Fulden; Turhal, S.; MAYADAĞLI, ALPASLAN
  • No Thumbnail Available
    PublicationMetadata only
    Radiation therapy for squamous cell cancer of the skin in a patient with xeroderma pigmentosum
    (2022-06-01T00:00:00Z) Altinok, Pelin; Tekçe, ERTUĞRUL; Ergün, Selmasönmez; Mayadagli, Alpaslan; TEKÇE, ERTUĞRUL; MAYADAĞLI, ALPASLAN
  • No Thumbnail Available
    PublicationMetadata only
    The Prognostic and Predictive Value of Expression of P-AKT in Patients with FIGO IIB Locally Advanced Cervical Cancer under Chemotherapy
    (2013-01-01T00:00:00Z) Kocak, Mihriban E.; Barisik, Nagehan O.; Mayadagli, Alpaslan; Gemici, Cengiz; Eren, Makbule; Naki, Murat; Ozseker, Naciye; Aksu, Atinc; MAYADAĞLI, ALPASLAN
    To evaluate the relation between expression of P-Akt and radiotherapy response, disease-free survival and overall survival in cervical cancer patients. A total of 50 patients with FIGO stage IIB locally advanced squamous cell cervical cancer treated primarily with chemoradiotherapy were included in the present study. All patients received external beam radiotherapy (EBRT; 46-50.4 Gy with 1.8-2 Gy of daily fraction, five times a week) followed by high-dose rate brachytherapy (HDR 26 Gy at point A, with 6.5 Gy per fraction a week for 4 weeks). Chemotherapy consisted of 40 mg/m2 cisplatin i.v. once a week for 5 weeks concomitant with external pelvic radiation. Paraffin-embedded, formalin-fixed primary tumor tissue was collected from each patient to identify P-Akt expression, retrospectively. The median follow up time for the study population was 30 (12-120) months. Expression of P-Akt was identified in 86% (43/50) of patients. Overall 3-years survival and disease free survival were 89.3% and 79%; respectively in the study population. There was no significant association between P-Akt staining and survival (89% vs 85.7%, p= 0.641) and disease-free survival (80% vs 88.2%, p= 0.498). There was no relation between expression of P-Akt and treatment response, size of the tumor, lymph node status, age, local and distant failures. Univariate analysis revealed significantly reduced overall 3-years survival and disease free survival only for patients with poor treatment response (p= 0.001). In multivariate analysis, treatment response was found to be statistically significant parameter only for DFS (p= 0.001). In conclusion, in our study, expression of P-Akt was detected in majority of cervical cancer patients. However no correlation was observed between P-Akt staining degree and treatment response
  • No Thumbnail Available
    PublicationMetadata only
    Elective bladder preservation with multimodality treatment for bladder cancer
    (2012-07-01T00:00:00Z) Mayadagli, Alpaslan; Kocak, M.; Demir, O.; Gul, S. Karabulut; Ozkan, A.; Parlak, C.; Yaprak, G.; Gumus, M.; MAYADAĞLI, ALPASLAN
    Purpose: To observe the outcome of maximal transurethral resection of bladder tumor (TURBT) followed by induction chemotherapy and concurrent chemoradiotherapy in medically inoperable patients with bladder cancer
  • No Thumbnail Available
    PublicationMetadata only
    Health-Related Quality of Life During Postoperative Chemoradiotherapy with Oral Uracil-Tegafur and Leucovorin in Rectal Cancer Patients
    (2013-05-01T00:00:00Z) Ozgen, Zerrin; Ozden, Sevgi; Dane, Faysal; ATASOY, BESTE MELEK; Akgunt, Zuleyha; Yumuk, P. Fulden; Mayadagli, Alpaslan; Turhal, N. Serdar; ABACIOGLU, Mehmet Ufuk; MAYADAĞLI, ALPASLAN
    Background/Aims: The objective of this study was to report on the quality of life of locally advanced rectal cancer patients that were treated with uracil-tegafur (UFT)/leucovorin (LV)-based concurrent chemoradiotherapy. Methodology: Twenty-five patients were enrolled into this prospective study. Radiotherapy (50.4Gy) was given with concurrent UFT (300mg/m(2)/day) and LV (30mg/day). Turkish versions of EORTC-QLQC30 and EORTC QLQCR38 were applied at the beginning (HROoL-1) and at the end (HRQoL-2) of chemoradiotherapy. Paired samples t-test was used to compare the difference of means for each scale between HRQoL1 and HRQoL2 and p values <0.05 were considered statistically significant. Results: Study compliance was 80.6%. From baseline to the end of chemoradiotherapy, the mean scores of dyspnea (p=0.006) diarrhea (p=0.005) and micturition (p=0.005) increased significantly. Chemotherapy side effects also increased at the end of therapy (p=0.07). Seventy-six percent (76%) of male patients replied to questions related to sexual problems and functions, whereas no female patients replied. Conclusions: Although, diarrhea and micturition are the major problems, quality of life scores indicate that concurrent oral fluoropyrimidine-based chemoradiotherapy is a feasible treatment.
  • No Thumbnail Available
    PublicationMetadata only
    THE EFFECT OF TUMOR SIZE ON OVERALL SURVIVAL IN PATIENTS WITH PT3 GASTRIC CANCER WHO UNDERWENT CURATIVE GASTRECTOMY
    (2010-01-01T00:00:00Z) Bilici, A.; UYGUN, KAZIM; Seker, M.; Aliustaoglu, M.; Temiz, S.; Oven, Ustaalioglu B.; AKSU, MAKSUT GÖRKEM; Salepci, T.; Mayadagli, Alpaslan; Gumus, M.; MAYADAĞLI, ALPASLAN